TXMDHIGH SIGNALFINANCIAL10-K

TXMD underwent a massive business restructuring with gross profit collapsing 98.1% from $68.6M to $1.3M while interest expense plummeted 99.2%, suggesting a major asset divestiture or business discontinuation.

The dramatic decline in gross profit alongside the massive reduction in interest expense indicates TXMD likely sold off or discontinued its main revenue-generating operations, fundamentally transforming the business model. The removal of language about raising capital "until we become cash flow positive" and addition of "exploration of potential strategic alternatives" suggests management may be pursuing a sale, merger, or complete business pivot rather than attempting to return to profitability.

Comparing 2026-03-30 vs 2025-03-27View on EDGAR →
FINANCIAL ANALYSIS

TXMD's financials reveal a company that has undergone a fundamental transformation, with gross profit collapsing from $68.6M to $1.3M (-98.1%) while interest expense dropped from $36.1M to $300K (-99.2%), strongly suggesting a major asset sale or business discontinuation. Despite the revenue collapse, net losses actually improved from -$2.2M to -$569K as the company dramatically reduced both SG&A (-46.7%) and R&D expenses (-32.1%), while debt declined $49.4M and cash position slightly improved. The overall picture suggests TXMD has essentially exited its previous business and is operating as a much smaller entity, possibly while exploring strategic alternatives.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
-99.2%
$36.1M→$300K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Gross Profit
P&L
-98.1%
$68.6M→$1.3M

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

Capital Expenditure
Cash Flow
-83.6%
$207K→$34K

Capex reduced 83.6% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Net Income
P&L
+73.9%
-$2.2M→-$569K

Net income grew 73.9% — bottom-line growth signals improving overall business health.

SG&A Expense
P&L
-46.7%
$8.9M→$4.7M

SG&A reduced 46.7% — improved cost efficiency or headcount reduction improving operating margins.

Revenue
P&L
+35.3%
$1.3M→$1.8M

Strong top-line growth of 35.3% — accelerating demand or successful expansion into new markets.

R&D Expense
P&L
-32.1%
$10.4M→$7.1M

R&D spending cut 32.1% — could signal cost discipline or concerning reduction in innovation investment.

Total Debt
Balance Sheet
-20.8%
$237.7M→$188.3M

Debt reduced 20.8% — deleveraging strengthens balance sheet and reduces financial risk.

Current Assets
Balance Sheet
+17.8%
$12.3M→$14.4M

Current assets grew 17.8% — improving short-term liquidity or inventory/receivables build.

Cash & Equivalents
Balance Sheet
+16.9%
$4.3M→$5.1M

Cash grew 16.9% — improving liquidity position supports investment and shareholder returns.

LANGUAGE CHANGES
NEW — 2026-03-30
PRIOR — 2025-03-27
ADDED
As of March 30, 2026 there were outstanding 11,574,362 shares of the registrant s common stock, par value $0.001 per share.
For example, statements regarding our operations, financial position, business strategy, exploration of potential strategic alternatives, and other plans and objectives for future operations, and assumptions and predictions about future demand, marketing, expenses and sales are all forward-looking statements.
Discontinued Operations to the consolidated financial statements included in this 2025 10-K Report for further details.
We may need to raise capital to provide additional liquidity to fund our operations.
We received gross proceeds of $1.15 million from the draw-down, before expenses.
We received gross proceeds of $2.0 million from the draw-down before expenses.
We continue to believe our estimated allowances for payer rebates and wholesale distributor fees are reasonable.
In August 2024 and in February 2025, we also received information from Mayne Pharma pertaining to the net working capital allowance for returns that differs significantly from our estimate of the allowance.
On April 8, 2025, we filed a lawsuit against Mayne Pharma in the United States District Court for the District of Delaware (the Mayne Lawsuit ) seeking damages for breach of contract, breach of the implied covenant of good faith and fair dealing, fraudulent inducement, and unjust enrichment related to Mayne Pharma s actions in relation to the License Agreement and the Transaction Agreement, primarily relating to the net working capital allowances and certain actions or inactions by Mayne Pharma relating thereto.
On June 20, 2025, we filed an amended complaint against Mayne Pharma and on July 22, 2025, Mayne Pharma filed a motion to dismiss the Mayne Lawsuit.
REMOVED
As of March 20, 2025, there were outstanding 11,574,362 shares of the registrant s common stock, par value $0.001 per share.
For example, statements regarding our operations, financial position, business strategy, and other plans and objectives for future operations, and assumptions and predictions about future demand, marketing, expenses and sales are all forward-looking statements.
See Note 2 - Discontinued Operations to the consolidated financial statements included in this Annual Report on Form 10-K for further details.
We may need to raise additional capital to provide additional liquidity to fund our operations until we become cash flow positive.
We received gross proceeds of $1.15 million from the draw down, before expenses.
We received gross proceeds of $2.0 million from the drawdown, before expenses.
The Company continues to believe its estimated allowances for payer rebates and wholesale distributor fees are reasonable and intends to resolve this matter through the processes permitted in the Transaction Agreement.
In August 2024, the Company received information from Mayne Pharma pertaining to the net working capital allowance for returns that differs significantly from the Company s estimate of the allowance.
As of December 31, 2024, the Company believed no additional accrual was required for amounts that may be owed for the allowance for returns under the Transaction Agreement.
The Company has not recorded any contingent gains or receivables for any such allowances.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →